Soligenix announces HyBryte clinical summary published

Soligenix (SNGX) announced today that a summary of all the clinical trials completed to date evaluating HyBryte as a treatment for cutaneous T-cell lymphoma has been published in the peer-reviewed medical journal Expert Opinion on Investigational Drugs. The publication “Topical Hypericin: A Promising Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma” is authored by Brian Poligone, MD, PhD, the founder and Medical Director of the Rochester Skin Lymphoma Medical Group and the Director of Cancer Biology Research for the Rochester General Hospital Research Institute who has extensive clinical experience evaluating HyBryte with his team’s participation in four HyBryte clinical studies. “We are pleased to have Dr. Poligone and his team review the compelling data generated from the HyBryte(TM) clinical program, enabling the medical community to evaluate its safety, efficacy and utility in early-stage CTCL,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “We look forward to continuing our work with Dr. Poligone and all our principal investigators as we move towards completing patient enrollment in the FLASH2 Phase 3 study later this year, with an interim analysis of this study expected in 2Q 2026.”